Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
01/12/17 SC 13G/A Amended Statement of Ownership
01/09/17 8-K Current report filing
01/05/17 4 Statement of Changes in Beneficial Ownership

Stock Quote

ACOR (Common Stock) $ 21.10 +0.60 (+2.93%) Volume: 572,459 MORE January 18, 2017

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.